NASDAQ: URGN · Life Sciences · 3 alerts · CIK 1668243
Share price
$28.10Close, Nov 16
Market cap
$1.38B
Shares outstanding
49.05MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All UroGen Pharma Ltd. filings on SEC EDGAR ↗
UroGen Pharma Ltd. reported Q3 2026 results featuring revenue from Jelmyto and Zusduri. The company significantly restructured its debt in early 2026, including a $100 million loan agreement with Pharmakon and the classification of $11.2 million in prepaid forward obligations as current liabilities.
UroGen Pharma reported third-quarter 2026 financial results, highlighted by $68.0 million in ZUSDURI revenue, representing 35% sequential growth. The company also announced that the FDA has accepted its NDA for UGN-103 with a PDUFA goal date of June 14, 2027, and reported a cash position of $215.4 million.
“We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.”
Liz Barrett, President and Chief Executive Officer of UroGen
“The U.S. Food and Drug Administration’s (FDA’s) acceptance of the UGN-103 New Drug Application (NDA) in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), together with our newly issued patent providing coverage into July 2044, further reinforce the long-term revenue potential of our bladder cancer portfolio.”
Liz Barrett, President and Chief Executive Officer of UroGen